期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药物基因组学和获得性尖端扭转室性心动过速 被引量：1

Pharmacogenomics and acquired TdP
原文传递
导出
摘要 药物基因组学在心脏安全性方面的研究目的是了解与基因因素相关的安全性变量,开发有助于评估临床试验早期药物安全性的工具,防止易感患者不适当用药。随着华法林基因组学研究成果及"2010院内获得性尖端扭转室速(TdP)防治建议"的发表,临床医生对TdP的发生原因和防治措施有了比较清晰的了解。目前市面上大约存在50种因延长QT间期而有潜在诱导TdP危险的药物,本文据此重点阐述药物诱导TdP的遗传学、药代动力学及药效动力学,以为临床医生提供防治思路。 The objective of pharmacogenomics study in cardiac is to find safety variables related to genetic factors,to develop tools that contribute to assess early drugs safety in clinical trials,and to prevent inappropriate medication in predisposing patients.With the warfarin genomics research and the 2010hospital acquired torsade de pointes（TdP）ventricular tachycardia prevention suggestions published,clinicians have a clear understanding about occurrence causes and control measures of TdP.There were about 50kinds of drugs in current market,and all have a potential risk of inducing TdP for extending QT interval.This review outlines expert opinions on phar-macokinetics,pharmacodynamics,and genetics of drugs-which induced TdP.
作者 洪葵 李菊香 程晓曙
机构地区 南昌大学第二附属医院心内科江西省医学遗传和基因治疗研究所
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第3期161-162,共2页 Journal of Clinical Cardiology
基金 国家重点基础研究发展计划973计划项目(No:2007CB512002) 国家自然科学基金项目(No:81070148)
关键词 室性心动过速 尖端扭转 获得性 药物基因组学 药物安全性 ventricular tachycardia TdP acquired pharmacogenomics drug safety
分类号 R541.7 [医药卫生—心血管疾病]
  • 相关文献

参考文献7

  • 1KLEIN T E, ALTMAN R B, ERIKSSON N, et al. Estimation of the warfarin dose with clinical and phar macogenetic dat[J]. N Engl J Med,2009,360,753-764.
  • 2DREW B J, ACKERMAN M J, FUNK M, et al. Pre vention of torsade de pointes in hospital settings : a scien- tific statement from the American Heart Association and the American College of Cardiology Foundation[J]. Cir culation, 2010,121 : 1047-1060.
  • 3VAN NOORD C, EIJQELSHEIM M, STRICKER B H. Drug-and non-drug-associated QT interval prolongation [J]. Br J Clin Pharmacol,2010,70 : 16-23.
  • 4AERSSENS J, PAULUSSEN A D. Pharmacogeneomics and acquired long QT syndrome[J]. Pharmcogenomics, 2005,6:259-270.
  • 5SHAH R R. Pharmacogenetic aspects of drug-induced torsade de pointes:potential tool for improving clinical drug development and prescribing [J]. Drug Saf, 2004,27 : 145-172.
  • 6ABERG K, ADKINS D E, LIU Y, et al. Genorne- wide association study of antipsychotic-induced QTc interval prolongation[J]. Pharmcogenomics, 2010,5 : [Epub ahead of print].
  • 7HARKCOM W T, ABBOTT G W. Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking[J].Expert Rev Cardiovasc Ther, 2010, 8: 1161-1173.

同被引文献16

  • 1Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potassium replacement in clinical practice= a contemporary review by the National Counci!. on Potassium in Clinical Practiee[J]. Arch Intern Med,2000,160(16) :2429 -2436.
  • 2Roden DM. Long QT syndrome:reduced repolarization reserve and the genetic link [J].J Intern Med,2006,259(1)=59-69.
  • 3Crotti L,Lundquist AL, Insolia R, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome[J]. Circulation, 2005,112 (9) :1251-1258.
  • 4Nor E, Cordeiro JM, Perez GJ, et al. A common single nucleotide polymorphism can exacerbate long QT type 2 syndrome leading to sudden infant death[J]. Circ Cardiovasc Genet,2010,3(2) :199-206.
  • 5Crotti L, H u D, Barajas-Martinez H, et al. Torsades de pointes following acute myocardial infarction: eidence for a deadly link with a common genetic variant[J]. Heart Rhythm, 2012,9 (7) : 1104-1112.
  • 6Hu D,Viskin S, Oliva A, et al. Novel mutation in the SCNSA gene associated with arrhythmic storm development during acute myocardial infarction[J]. Heart Rhythm, 2007, 4 ( 8 ) : 1072-1080.
  • 7Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study[J]. Nat Genet,2009,41(4):399-406.
  • 8Kahn IA. Long QT syndrome: diagnosis and management[J]. Am Heart J,2002,143(1) :7-14.
  • 9Lu T, Lee HC, Kabat J A, et al. Modulation of rat cardiac sodium channel by the stimulatory G protein alpha subunit[J]. J Physio,1999,5tS(Pt2) :371-384.
  • 10Fabritz L, Kirchhof P, Franz MR, et al. Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in amouse model of proarrhythmia[J]. Basic Res Cardiol, 2003,98 (1) : 25- 32.

引证文献1

二级引证文献7

临床心血管病杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部